BR112017008220A2 - terapia para inibição de replicação do vírus de rna de filamento único - Google Patents

terapia para inibição de replicação do vírus de rna de filamento único

Info

Publication number
BR112017008220A2
BR112017008220A2 BR112017008220-9A BR112017008220A BR112017008220A2 BR 112017008220 A2 BR112017008220 A2 BR 112017008220A2 BR 112017008220 A BR112017008220 A BR 112017008220A BR 112017008220 A2 BR112017008220 A2 BR 112017008220A2
Authority
BR
Brazil
Prior art keywords
filovirus
individual
stranded rna
rna virus
virus replication
Prior art date
Application number
BR112017008220-9A
Other languages
English (en)
Inventor
Fathi Reza
Ben-Asher Dror
Goldberg Guy
Original Assignee
Redhill Biopharma Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redhill Biopharma Ltd. filed Critical Redhill Biopharma Ltd.
Publication of BR112017008220A2 publication Critical patent/BR112017008220A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção refere-se às composições farmacêuticas que mostram a capacidade de inibir ou suprimir a replicação de um filovírus em um indivíduo. as composições descritas são úteis para tratar, reverter, ou reduzir a disseminação de infecções por filovírus. um método inclui administrar pelo menos um agente da presente descrição a um indivíduo infectado com ou exposto a um filovírus, em que a etapa de administração é realizada durante um período de tempo adequado, de modo que o indivíduo seja tratado; e determinar se o indivíduo foi tratado, em que a etapa de determinação inclui medir uma inibição em replicação viral, medir um decréscimo em carga viral, ou reduzir pelo menos um sintoma associado com o filovírus.
BR112017008220-9A 2014-10-24 2015-10-23 terapia para inibição de replicação do vírus de rna de filamento único BR112017008220A2 (pt)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201462068477P 2014-10-24 2014-10-24
US201462068465P 2014-10-24 2014-10-24
US201462068487P 2014-10-24 2014-10-24
US201462068469P 2014-10-24 2014-10-24
US201462068492P 2014-10-24 2014-10-24
US62/068,469 2014-10-24
US62/068,487 2014-10-24
US62/068,465 2014-10-24
US62/068,492 2014-10-24
US62/068,477 2014-10-24
US201562188030P 2015-07-02 2015-07-02
US62/188,030 2015-07-02
PCT/IB2015/002173 WO2016063134A1 (en) 2014-10-24 2015-10-23 Therapy for inhibition of single-stranded rna virus replication

Publications (1)

Publication Number Publication Date
BR112017008220A2 true BR112017008220A2 (pt) 2018-01-09

Family

ID=55760346

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017008220-9A BR112017008220A2 (pt) 2014-10-24 2015-10-23 terapia para inibição de replicação do vírus de rna de filamento único

Country Status (12)

Country Link
US (5) US9974800B2 (pt)
EP (2) EP4134076A1 (pt)
JP (1) JP6625631B2 (pt)
KR (1) KR20170070234A (pt)
CN (2) CN107106525B (pt)
AU (2) AU2015334590B2 (pt)
BR (1) BR112017008220A2 (pt)
CA (1) CA2965258C (pt)
IL (1) IL251847A0 (pt)
MX (1) MX2017005350A (pt)
SG (1) SG11201703307WA (pt)
WO (1) WO2016063134A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4134076A1 (en) * 2014-10-24 2023-02-15 Redhill Biopharma Ltd. Therapy for inhibition of single-stranded rna virus replication
RU2727474C2 (ru) * 2015-10-06 2020-07-21 Редхилл Байофарма Лтд. Виды комбинированной терапии для лечения рака
CN108853106B (zh) * 2017-05-09 2021-02-02 中国食品药品检定研究院 亚胺吩嗪类化合物作为狂犬病病毒抑制剂的用途
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
DE102018217334A1 (de) 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
WO2020185637A1 (en) * 2019-03-08 2020-09-17 The Texas A&M University System Rose rosette virus infectious clones and uses thereof
US20210244705A1 (en) * 2020-02-07 2021-08-12 Centre For Digestive Diseases Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection
BR112022017923A2 (pt) * 2020-03-10 2022-10-18 Redhill Biopharma Ltd Tratamento de infecção por coronavírus
EP3932409A1 (en) * 2020-06-29 2022-01-05 Consejo Superior de Investigaciones Científicas (CSIC) Compounds for the treatment and prevention of viral infections caused by coronaviruses
US11298412B2 (en) 2020-07-16 2022-04-12 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6335339B1 (en) * 1998-01-13 2002-01-01 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
AP2001002051A0 (en) * 1998-07-15 2001-03-31 Hassan Jomaa Phosphorous organic compounds and their use.
ES2477118T3 (es) * 2002-11-18 2014-07-15 Polaris Group Método para inhibir la replicaci�n viral in vivo
US7338961B2 (en) * 2005-06-17 2008-03-04 Apogee Biotechnology Corporation Sphingosine kinase inhibitors
GB0803707D0 (en) 2008-02-28 2008-04-09 Cambridge Entpr Ltd Antiviral agent
KR101420094B1 (ko) * 2010-10-27 2014-07-17 (주)바이오니아 다양한 생체시료분석을 위한 전자동실시간정량증폭장비, 다양한 생체시료분석을 위한 자동정제 및 반응준비 장치, 전자동 핵산정제 및 실시간 정량 유전자증폭 방법, 전자동 핵산정제방법, 실시간정량ｐｃｒ을 이용한 병원균의 전자동 생균수검사방법, 정량면역ｐｃｒ을 이용한 전자동 항원농도획득방법 및 타겟항원에 라벨링된 부착용 타겟핵산의 정제방법
WO2012166859A2 (en) * 2011-06-01 2012-12-06 The Curators Of The University Of Missouri Modulation of sphingosine 1-phosphate metabolizing enzymes for the treatment of negative-strand rna virus infections
EP4134076A1 (en) * 2014-10-24 2023-02-15 Redhill Biopharma Ltd. Therapy for inhibition of single-stranded rna virus replication
RU2727474C2 (ru) * 2015-10-06 2020-07-21 Редхилл Байофарма Лтд. Виды комбинированной терапии для лечения рака

Also Published As

Publication number Publication date
EP4134076A1 (en) 2023-02-15
US11786541B2 (en) 2023-10-17
US10543222B2 (en) 2020-01-28
US20200155585A1 (en) 2020-05-21
EP3209290A1 (en) 2017-08-30
JP6625631B2 (ja) 2019-12-25
US20240108643A1 (en) 2024-04-04
US20180318328A1 (en) 2018-11-08
CN107106525B (zh) 2021-03-19
AU2019271958B2 (en) 2020-03-05
IL251847A0 (en) 2017-06-29
JP2017531673A (ja) 2017-10-26
AU2019271958A1 (en) 2019-12-19
CN107106525A (zh) 2017-08-29
WO2016063134A1 (en) 2016-04-28
AU2015334590A1 (en) 2017-05-18
CA2965258C (en) 2023-09-19
MX2017005350A (es) 2017-08-15
CN112999222A (zh) 2021-06-22
AU2015334590B2 (en) 2019-08-29
CN112999222B (zh) 2024-05-28
CA2965258A1 (en) 2016-04-28
EP3209290A4 (en) 2018-11-14
US20210369754A1 (en) 2021-12-02
SG11201703307WA (en) 2017-05-30
US11090325B2 (en) 2021-08-17
US9974800B2 (en) 2018-05-22
KR20170070234A (ko) 2017-06-21
US20160113954A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
BR112017008220A2 (pt) terapia para inibição de replicação do vírus de rna de filamento único
CY1123845T1 (el) Τοπικα φαρμακευτικα σκευασματα για την αγωγη φλεγμονωδων καταστασεων
BR112018009009A2 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
NZ745328A (en) Methods for treating filoviridae virus infections
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
NZ759766A (en) Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety
MX2021005087A (es) Compuestos de formula i para usarse en el tratamiento de infecciones por virus arenaviridae y coronaviridae.
BR112017003302A2 (pt) sal de adição de ácido do composto inibidor de trk
CL2016000805A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
BR112018003212A2 (pt) diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3
EA201791916A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
CY1122177T1 (el) Δοτες νιτροξυλιου με βελτιωμενο θεραπευτικο δεικτη
MX2022009352A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
EA201790160A1 (ru) Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d
BR112019004560A2 (pt) tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv
BR112016021648A2 (pt) novos compostos
CY1120158T1 (el) Γλουταρυλο ισταμινη για την αγωγη και προφυλαξη παθησεων προκαλουμενων απο ιους που περιεχουν (+)rna
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112016007462A2 (pt) fitonutrientes anti-inflamatórios para uso no tratamento ou prevenção de sinovite
BR112019006802A2 (pt) compostos e métodos para diagnóstico e tratamento de infecções virais
BR112018003836A2 (pt) combinações de inibidor de btk para tratar mieloma múltiplo
PH12016502039A1 (en) Potent and selective inhibitors of hepatitis c virus
BR112017014914A2 (pt) terapia combinada para hipertensão pulmonar
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]